

5 December 2022

Section 708A(5)(e) Notice

This notice is given by Pharmaxis Ltd (ACN 082 811 630) (ASX: PXS) (**Company**) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).


The Company refers to its announcement on 29 November 2022 regarding approval by shareholders at the 2022 Annual General Meeting of the second tranche of a share placement to raise approximately \$5.1 million. The Company has today issued 84,295,725 new fully paid ordinary shares at an issue price of \$0.06 per share (**New Shares**).

The Company confirms the following:

1. The New Shares were offered for issue without disclosure to investors under Part 6D.2 of the Corporations Act.
2. This notice is being given under section 708A(5)(e) of the Corporations Act.
3. As at the date of this notice, the Company has complied with:
 - a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - b) sections 674 and 674A of the Corporations Act.
4. As at the date of this notice, there is no “excluded information” of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be set out in this notice under section 708A(6)(e) of the Corporations Act.

This announcement has been authorised for release by the Board of the Company.

Pharmaxis Ltd



David McGarvey
Chief Financial Officer / Company Secretary